BamSEC and AlphaSense Join Forces
Learn More

Kronos Bio Inc. – Material Contracts

Formerly NASDAQ: KRON
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 29 pages Form of Contingent Value Rights Agreement
12/34/56
EX-10.13
from 10-K 16 pages Transition Agreement and Mutual General Release
12/34/56
EX-10.1
from 8-K 7 pages Executive Employment Agreement
12/34/56
EX-10.14
from 10-K 6 pages January 24, 2024 Barbara Kosacz Re: Separation Agreement Dear Barbara: This Letter Sets Forth the Terms of the Separation Agreement (This "Agreement") That Kronos Bio, Inc. (The "Company") Is Offering to You to Aid in Your Employment Transition From the Company
12/34/56
EX-10.13
from 10-K 7 pages January 24, 2024 Jorge Dimartino, M.D., PH.D. Re: Separation Agreement Dear Jorge: This Letter Sets Forth the Terms of the Separation Agreement (This “Agreement”) That Kronos Bio, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition From the Company. 1.separation Date. You Agree and Acknowledge That Your Company Employment Will Terminate on February 16, 2024 (The “Separation Date”). as of and Following the Separation Date,
12/34/56
EX-10.1
from 10-Q 5 pages Confidential Consulting Agreement
12/34/56
EX-10.16
from 10-K 96 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Kronos Bio, Inc. Treats as Private or Confidential. Collaboration and License Agreement Between Kronos Bio, Inc. and Genentech, Inc. and F. Hoffmann-La Roche Ltd as of January 6, 2023
12/34/56
EX-10.3
from 10-Q/A 16 pages Kronos Bio, Inc. Severance and Change in Control Plan
12/34/56
EX-10.1
from 10-Q/A 3 pages Kronos Bio, Inc. Non-Employee Director Compensation Policy Adopted: September 30, 2020 Amended: February 16, 2022
12/34/56
EX-10.3
from 10-Q 4 pages 272536548 V2 2 Each of the Undersigned Committee Members Has Signed This Action by Unanimous Written Consent as of the Date Set Forth Across From His or Her Name Below: Directors: Arie S. Belldegrun, M.D. Date Marianne De Backer, PH.D. Date Roshawn Blunt Date Docusign Envelope Id: Fc565efd-41fa-4c85-9e97-977ce7113865 7/31/2022 8/2/2022 8/1/2022
12/34/56
EX-10.1
from 10-Q 18 pages Material contract
12/34/56
EX-10.1
from 8-K 15 pages Kronos Bio, Inc. Severance and Change in Control Plan
12/34/56
EX-10.13
from 10-K 13 pages May 28, 2020 Christopher Dinsmore, PH.D. 24 Chester Street Newton, Ma 02461 Re: Employment Letter 1. Title; Reporting; Duties. 3. Compensation
12/34/56
EX-10.1
from 10-Q 14 pages Second Amendment to Office Lease
12/34/56
EX-10.13
from 10-K 13 pages May 28, 2020 Christopher Dinsmore, PH.D. 24 Chester Street Newton, Ma 02461 Re: Employment Letter 1. Title; Reporting; Duties. 3. Compensation
12/34/56
EX-10.1
from 10-Q 8 pages July 15, 2020 Barbara A. Kosacz 28140 Story Hill Lane Los Altos Hills, Ca 94022 Re: Employment Letter 1. Title; Reporting; Duties. 3. Compensation. (A)base Salary. You Shall Receive an Annual Base Salary Equal to Three Hundred Fifty Thousand Dollars (US$350,000), Which Shall Be Payable in Accordance With the Company’s Payroll Practices
12/34/56
EX-10.12
from S-1/A 2 pages Kronos Bio, Inc. Non-Employee Director Compensation Policy Adopted: September 30, 2020
12/34/56
EX-10.5
from S-1/A 13 pages April 30, 2018 Norbert Bischofberger, PH.D. Re: Employment Letter 1. Title; Reporting; Duties
12/34/56
EX-10.4
from S-1/A 15 pages Kronos Bio, Inc. 2020 Employee Stock Purchase Plan Adopted by the Board of Directors: October 1, 2020 Approved by the Stockholders: October 2, 2020 Ipo Date: , 2020
12/34/56
EX-10.3
from S-1/A 54 pages Kronos Bio, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: October 1, 2020 Approved by the Stockholders: October 2, 2020
12/34/56